Risedronic acid and zoledronic acid in the treatment of postmeneopausal osteoporosis

Abstract

Recently, every time more potent new bisphosphonates, have been developed for the treatment of postmeneopausal osteoporosis. Risedronic acid is a aminobisphosphonate who has shown a reduction in the risk of vertebral fracture and also nonvertebral and hip fractures. It has been approved in Spain for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis. Usually it is well tolerated and it is administered in a weekly oral dose. Zoledronic acid has also shown its capacity of reducing the risk of vertebral fracture and also nonvertebral and hip fractures It must be administered by intravenous inyection once a year. It has not been approved for its use in the treatment of postmenopausal osteoporosis and also male and glucocorticoid induced osteoporosis yet. It can be prescribed only in Hospitals. Both drugs are very safe, secure and valid for the treatment of osteoporosis. The election of one or another bisphosphonate depends on clinical circumstances and the opinion of every patient.